Medindia

X

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference

Thursday, October 18, 2007 General News J E 4
Advertisement
DUBLIN, Calif., Oct. 17 SuperGen Inc.(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapiddevelopment and commercialization of therapies for solid tumors andhematological malignancies, today announced that multiple abstracts have beenaccepted for poster presentations at the AACR-NCI-EORTC InternationalConference from Oct. 22-26 at the Moscone Center in San Francisco.

The poster presentations will focus on data concerning many of SuperGen'scurrent oncology programs including the lead clinical compound, MP470, and itsability to suppress the repair of double stranded DNA breaks followingtreatment with DNA-damaging agents.

In addition to the poster presentations listed below, data on SuperGen'shypomethylating agent, S110, will be presented by Dr. Peter A. Jones onWednesday, Oct. 24 at 8:00 a.m. in Plenary Session 3: Epigenetic Targets.

About SuperGen

Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical companydedicated to the discovery, rapid development and commercialization oftherapies for solid tumors and hematological malignancies. SuperGen isdeveloping a number of therapeutic anticancer products focused on kinase andcell signaling inhibitors and DNA methyltransferase inhibitors. For moreinformation about SuperGen, please visit http://www.supergen.com.

Forward-Looking Statements

This news release contains certain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements are typically preceded by words such as "believes," "expects,""anticipates," "intends," "will," "may," "should," or similar expressions.These forward-looking statements are not guarantees of future performance andinvolve a number of risks and uncertainties that may cause actual results todiffer materially from the results discussed in these statements. Factors thatmight cause the company's results to differ materially from those expressed orimplied by such forward-looking statements include, but are not limited to,the ability to discover, develop and move target compounds into clinicaldevelopment and other risks and uncertainties detailed from time to time inthe company's filings with the Securities and Exchange Commission includingits most recently filed Form 10-Q and 10-K. SuperGen, Inc. undertakes no dutyto update any of these forward-looking statements to conform them to actualresults.SuperGen's schedule of presentations is as follows: Poster Date Time (PDT) Abstract # and Title Number/Session Tuesday, 12:30 p.m.- # 1026 - MP470 #A173 Oct. 23 2:30 p.m. suppresses repair of double-strand breaks Poster Session A 5:30 p.m.- following treatment 7:30 p.m. with DNA-damaging agents Wednesday, 12:30 p.m.- # 1038 - The #B140 Oct. 24 2:30 p.m. decitabine-derived demethylating Poster Session B 5:30 p.m.- dinucleotide, S110 7:30 p.m. shows improved activity due to increased drug delivery and stability Thursday, 12:30 p.m.- # 907 - Effect of #C200 Oct. 25 2:30 p.m. small molecule inhibitors of JAK2 Poster Session C 5:30 p.m.- kinase on modulating 7:30 p.m. signaling cascades downstream of cytokine receptors Thursday, 12:30 p.m.- # 985 - A small #C208 Oct. 25 2:30 p.m. molecule inhibitor of
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Organon's Asenapine Further Demonstrates Efficacy ...
S
Health Canada Approves ATRIPLA(R) (efavirenz 600 m...